Phenotypes related to Risk-Reducing Surgery, Prevention ~ Breast Cancer — Risk / Phenotype

List was last updated on Nov 23, 2019 @ 7:41 am.


    • Sexual function, menopausal symptoms, depression and cancer worry in women with BRCA mutations.
    • Powell CB, Alabaster A, Le A, Stoller N, Armstrong MA, Raine-Bennett T.
    • Psychooncology. 2019 Oct 26. doi: 10.1002/pon.5253. [Epub ahead of print]
    • Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199).
    • Mai PL, Miller A, Gail MH, Skates S, Lu K, Sherman ME, Ioffe OB, Rodriguez G, Cohn DE, Boggess J, Rutherford T, Kauff ND, Rader JS, Phillips KA, DiSilvestro PA, Olawaiye AB, Ridgway MR, Greene MH, Piedmonte M, Walker JL.
    • JNCI Cancer Spectr. 2019 Oct 8; pkz075. doi: 10.1093/jncics/pkz075. eCollection 2019 Oct.

    Commentary:

    Preventing breast cancer in high risk women: is there still a role for oophorectomy?

    • Oncological Safety of Lipofilling in Healthy BRCA Carriers After Bilateral Prophylactic Mastectomy: A Case Series.
    • Quoc CH, Dias LPN, Braghiroli OFM, Martella N, Giovinazzo V, Piat JM.
    • Eur J Breast Health. 2019 Oct 1;15(4):217-221. doi: 10.5152/ejbh.2019.5013. eCollection 2019 Oct.
    • Risk-reducing mastectomy in BRCA carriers: survival is not the issue.
    • Neven P, Punie K, Wildiers H, Willers N, Van Ongeval C, Van Buggenhout G, Legius E.
    • Breast Cancer Res Treat. 2019 Sep 20. doi: 10.1007/s10549-019-05440-4. [Epub ahead of print]
    • Letter, Comment

    Letter, Reply:

    Risk-reducing mastectomy in BRCA mutation carriers: survival is one of the issues-author's reply.

    Original Research:

    Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.

    • Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?
    • Evans DG, Howell SJ, Howell A.
    • Fam Cancer. 2019 Aug 23. doi: 10.1007/s10689-019-00142-8. [Epub ahead of print]

    Original Research:

    Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.

    • Use of Mammographic Measurements to Predict Complications After Nipple-Sparing Mastectomy in BRCA Mutation Carriers.
    • Park KU, Weiss A, Rosso K, Yi M, Hunt K, Kuerer H, Hanson SE, Candelaria R, Tevis S, Thompson A.
    • Ann Surg Oncol. 2019 Aug 9. doi: 10.1245/s10434-019-07704-1. [Epub ahead of print]
    • A Microsimulation Model for Evaluating the Effectiveness of Cancer Risk Management for BRCA Pathogenic Variant Carriers: miBRovaCAre.
    • Petelin L, Hossack L, Mitchell G, Liew D, Trainer AH, James PA.
    • Value Health. 2019 Aug;22(8):854-862. doi: 10.1016/j.jval.2019.03.008. Epub 2019 May 17.
    • Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
    • Chang J, Seng S, Yoo J, Equivel P, Lum SS.
    • Ann Surg Oncol. 2019 Jul 24. doi: 10.1245/s10434-019-07595-2. [Epub ahead of print]
    • Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.
    • Heemskerk-Gerritsen BAM, Jager A, Koppert LB, Obdeijn AI, Collée M, Meijers-Heijboer HEJ, Jenner DJ, Oldenburg HSA, van Engelen K, de Vries J, van Asperen CJ, Devilee P, Blok MJ, Kets CM, Ausems MGEM, Seynaeve C, Rookus MA, Hooning M.
    • Breast Cancer Res Treat. 2019 Jul 13. doi: 10.1007/s10549-019-05345-2. [Epub ahead of print]

    Commentary:

    Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?

    Letter, Comment:

    Risk-reducing mastectomy in BRCA carriers: survival is not the issue.

    Letter, Reply:

    Risk-reducing mastectomy in BRCA mutation carriers: survival is one of the issues-author's reply.

    • How Safe Is Hormone Replacement Therapy After Risk-Reducing Salpingo-oophorectomy in Women With BRCA Mutations?
    • Markman M.
    • Medscape Oncology. 2019 Jun 14.

    Original research:

    Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.

    • Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.
    • Kotsopoulos J, Lubinski J, Lynch HT, Tung N, Armel S, Senter L, Singer CF, Fruscio R, Couch F, Weitzel JN, Karlan B, Foulkes WD, Moller P, Eisen A, Ainsworth P, Neuhausen SL, Olopade O, Sun P, Gronwald J, Narod SA; Hereditary Breast Cancer Clinical Study Group.
    • Breast Cancer Res Treat. 2019 Jun;175(2):443-449. doi: 10.1007/s10549-019-05162-7. Epub 2019 Feb 12.
    • Women's health 2019: Osteoporosis, breast cancer, contraception, and hormone therapy.
    • Moreno AC, Sahni SK, Smith TL, Batur P.
    • Cleve Clin J Med. 2019 Jun;86(6):400-406. doi: 10.3949/ccjm.86a.18130.
    • Residual glandular tissue (RGT) in BRCA1/2 germline mutation carriers with unilateral and bilateral prophylactic mastectomies.
    • Grinstein O, Krug B, Hellmic M, Siedek F, Malter W, Burke C, Schmutzler R, Maintz D, Rhiem K.
    • Surg Oncol. 2019 Jun;29:126-133. doi: 10.1016/j.suronc.2019.04.009. Epub 2019 May 3.
    • Sentinel lymph node biopsy following previous axillary surgery in recurrent breast cancer.
    • Sávolt Á, Cserni G, Lázár G, Maráz R, Kelemen P, Kovács E, Győrffy B, Udvarhelyi N, Vörös A, Ormándi K, Mátrai Z.
    • Eur J Surg Oncol. 2019 May 16. pii: S0748-7983(19)30454-8. doi: 10.1016/j.ejso.2019.05.016. [Epub ahead of print]
    • Clinical background and outcomes of risk-reducing salpingo-oophorectomy for hereditary breast and ovarian cancers in Japan.
    • Nomura H, Sekine M, Yokoyama S, Arai M, Enomoto T, Takeshima N, Nakamura S.
    • Int J Clin Oncol. 2019 May 4. doi: 10.1007/s10147-019-01456-4. [Epub ahead of print]
    • Who should get a contralateral prophylactic mastectomy for breast cancer?
    • Bedrosian I, Parker PA, Brewster AM.
    • Cancer. 2019 May 1;125(9):1400-1403. doi: 10.1002/cncr.31915. Epub 2019 Jan 15.
    • Case report, review
    • Differences between screen-detected and interval breast cancers among BRCA mutation carriers.
    • Pilewskie M, Zabor EC, Gilbert E, Stempel M, Petruolo O, Mangino D, Robson M, Jochelson MS.
    • Breast Cancer Res Treat. 2019 May;175(1):141-148. doi: 10.1007/s10549-018-05123-6. Epub 2019 Jan 23.
    • Analysis of Outcomes in Patients With BRCA1/2 Breast Cancer Mutations Treated With Accelerated Partial Breast Irradiation (APBI).
    • Ahmed F, Christos PJ, Singh P, Parashar B, Wernicke AG.
    • Am J Clin Oncol. 2019 Apr 9. doi: 10.1097/COC.0000000000000542. [Epub ahead of print]
    • Multidisciplinary management of CDH1 germinal mutation and prophylactic management hereditary lobular breast cancer: A case report.
    • Mirandola S, Pellini F, Granuzzo E, Lorenzi M, Accordini B, Ulgelmo M, Invento A, Lombardi D, Caldana M, Pollini GP.
    • Int J Surg Case Rep. 2019 Apr 5;58:92-95. doi: 10.1016/j.ijscr.2019.03.053. [Epub ahead of print]
    • Evolving indications and long-term oncological outcomes of risk-reducing bilateral nipple-sparing mastectomy.
    • Grobmyer SR, Pederson HJ, Valente SA, Al-Hilli Z, Radford D, Djohan R, Yetman R, Eng C, Crowe JP.
    • BJS Open. 2018 Nov 26;3(2):169-173. doi: 10.1002/bjs5.50117. eCollection 2019 Apr.
    • Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.
    • Gordhandas S, Norquist BM, Pennington KP, Yung RL, Laya MB, Swisher EM.
    • Gynecol Oncol. 2019 Apr;153(1):192-200. doi: 10.1016/j.ygyno.2018.12.014. Epub 2019 Jan 17.
    • Review

    Commentary: How Safe Is Hormone Replacement Therapy After Risk-Reducing Salpingo-oophorectomy in Women With BRCA Mutations? (Medscape Oncology)

    • Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines.
    • Vermeulen RFM, Korse CM, Kenter GG, Brood-van Zanten MMA, Beurden MV.
    • Climacteric. 2019 Mar 25:1-9. doi: 10.1080/13697137.2019.1582622. [Epub ahead of print]
    • Review
    • Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy.
    • Menkiszak J, Chudecka-Głaz A, Cymbaluk-Płoska A, Celewicz A, Kojs Z, Szajda M, Świniarska M, Bedner R, Jurczak A, Celewicz M, Cieszyńska M, Lubiński J, Gronwald J.
    • Hered Cancer Clin Pract. 2019 Mar 14;17:10. doi: 10.1186/s13053-019-0109-5. eCollection 2019.
    • Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk.
    • Terry MB, Daly MB, Phillips KA, Ma X, Zeinomar N, Leoce N, Dite GS, MacInnis RJ, Chung WK, Knight JA, Southey MC, Milne RL, Goldgar D, Giles GG, Weideman PC, Glendon G, Buchsbaum R, Andrulis IL, John EM, Buys SS, Hopper JL.
    • J Natl Cancer Inst. 2019 Mar 1;111(3):331-334. doi: 10.1093/jnci/djy182.

    Press: Oophorectomy to Reduce Ovarian-cancer Risk Not Tied to Breast-cancer Risk. (Medscape Oncology)

    • Evaluation of screening and risk-reducing surgery for women followed in a high-risk breast/ovarian cancer clinic: it is all about the tubes in BRCA mutation carriers.
    • Stewart ME, Knisely AT, Sullivan MW, Ring KL, Modesitt SC.
    • Gynecol Oncol Rep. 2019 Feb 1;28:18-22. doi: 10.1016/j.gore.2019.01.010. eCollection 2019 May.
    • Risk Reduction and Survival Benefit of Risk-Reducing Salpingo-oophorectomy in Hereditary Breast Cancer: Meta-analysis and Systematic Review.
    • Xiao YL, Wang K, Liu Q, Li J, Zhang X, Li HY.
    • Clin Breast Cancer. 2019 Feb;19(1):e48-e65. doi: 10.1016/j.clbc.2018.09.011. Epub 2018 Oct 4.
    • Prophylactic Versus Therapeutic Mastectomy: A Contemporary Analysis of the ACS-NSQIP Database.
    • Hendrix RJ, Lee C, Friedrich AK, Rouanet E, Larkin AC, LaFemina J.
    • Clin Breast Cancer. 2019 Jan 31. pii: S1526-8209(19)30050-3. doi: 10.1016/j.clbc.2019.01.008. [Epub ahead of print]
    • Risk-Reducing Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Complex Discussion.
    • Domchek SM.
    • JAMA. 2019 Jan 1;321(1):27. doi: 10.1001/jama.2018.18942.
    • Review, Commentary
    • High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound: findings from the Hereditary Breast and Ovarian Cancer Registration 2016 in Japan.
    • Yamauchi H, Okawa M, Yokoyama S, Nakagawa C, Yoshida R, Suzuki K, Nakamura S, Arai M.
    • Breast Cancer Res Treat. 2018 Dec;172(3):679-687. doi: 10.1007/s10549-018-4953-1. Epub 2018 Sep 10.
    • Does anti-Müllerian hormone predict change in menopausal symptoms following risk-reducing salpingo-oophorectomy? A prospective observational study.
    • Vermeulen RFM, van Beurden M, Gaarenstroom KN, Teunis T, Kieffer JM, Aaronson NK, Kenter GG, Korse CM.
    • Climacteric. 2018 Dec;21(6):574-580. doi: 10.1080/13697137.2018.1512965. Epub 2018 Oct 8.
    • Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis.
    • Marchetti C, De Felice F, Boccia S, Sassu C, Di Donato V, Perniola G, Palaia I, Monti M, Muzii L, Tombolini V, Benedetti Panici P.
    • Crit Rev Oncol Hematol. 2018 Dec;132:111-115. doi: 10.1016/j.critrevonc.2018.09.018. Epub 2018 Oct 3.
    • Review
    • Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer.
    • Straub MM, Podoll MB, David SN, Wiesner GL, Desouki MM.
    • Ann Diagn Pathol. 2018 Oct;36:28-30. doi: 10.1016/j.anndiagpath.2018.06.003. Epub 2018 Jun 27.
    • Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study.
    • Minig L, Cabrera S, Oliver R, Couso A, Rubio MJ, Iacoponi S, Martin-Salamanca MB, Carballo-Rastrilla S, Cádenas-Rebollo JM, García-Garcia A, Gil-Ibáñez B, Juan-Fita MJ, Patrono MG.
    • Clin Transl Oncol. 2018 Oct;20(10):1337-1344. doi: 10.1007/s12094-018-1865-9. Epub 2018 Apr 5.
    • Risk management adherence following genetic testing for hereditary cancer syndromes: a Singaporean experience.
    • Courtney E, Chin XW, Yuen J, Li ST, Chen Y, Allen JC Jr, Tan V, Lim GH, Ngeow J.
    • Fam Cancer. 2018 Oct;17(4):621-626. doi: 10.1007/s10689-018-0071-9.
    • Hormone therapy and breast cancer risk after ovary removal in women with a BRCA1 mutation.
    • [No author given]
    • FORCE. XRAYS. 2018 Sep 7.

    Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.

    • Surgery for BRCA, TP53 and PALB2: a literature review.
    • Song CV, Teo SH, Taib NA, Yip CH.
    • Ecancermedicalscience. 2018 Aug 29;12:863. doi: 10.3332/ecancer.2018.863. eCollection 2018.
    • Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    • Eleje GU, Eke AC, Ezebialu IU, Ikechebelu JI, Ugwu EO, Okonkwo OO.
    • Cochrane Database Syst Rev. 2018 Aug 24;8:CD012464. doi: 10.1002/14651858.CD012464.pub2.
    • Meta-Analysis, Review
    • Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.
    • Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, Armel S, Lynch HT, Senter L, Eisen A, Singer CF, Foulkes WD, Jacobson MR, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.
    • JAMA Oncol. 2018 Aug 1;4(8):1059-1065. doi: 10.1001/jamaoncol.2018.0211.

    Research News: Hormone therapy and breast cancer risk after ovary removal in women with a BRCA1 mutation. (FORCE, XRAYS)

    Commentary, Video: Menopausal Hormone Therapy and Risk for Breast Cancer in BRCA1 Mutation Carriers. (Medscape)

    • The risk of stroke after bilateral salpingo-oophorectomy at hysterectomy for benign diseases: A nationwide cohort study.
    • Lai JC, Chou YJ, Huang N, Chen HH, Wang KL, Wang CW, Shen IH, Chang HC.
    • Maturitas. 2018 Aug;114:27-33. doi: 10.1016/j.maturitas.2018.05.007. Epub 2018 May 19.
    • Mortality and Risk of Cancer After Prophylactic Bilateral Oophorectomy in Women With a Family History of Cancer.
    • Abildgaard J, Ahlström MG, Daugaard G, Nielsen DL, Tønnes Pedersen A, Lindegaard B, Obel N.
    • JNCI Cancer Spectrum. 2018 Jul 1;2(3):pky034. doi: 10.1093/jncics/pky034.
    • Uptake of risk-reducing surgery in BRCA gene carriers in Wales, UK.
    • Long J, Evans TG, Bailey D, Lewis MH, Gower-Thomas K, Murray A.
    • Breast J. 2018 Jul;24(4):580-585. doi: 10.1111/tbj.12978. Epub 2017 Dec 29.
    • Prophylactic salpingo-oophorectomy & surgical menopause for inherited risks of cancer: the need to identify biomarkers to assess the theoretical risk of premature coronary artery disease.
    • Batulan Z, Maarouf N, Shrivastava V, O'Brien E.
    • Womens Midlife Health. 2018 Apr 27;4:7. doi: 10.1186/s40695-018-0037-y. eCollection 2018.
    • Risk-reducing mastectomy for the prevention of primary breast cancer.
    • Carbine NE, Lostumbo L, Wallace J, Ko H.
    • Cochrane Database Syst Rev. 2018 Apr 5;4:CD002748. doi: 10.1002/14651858.CD002748.pub4.
    • Review, Meta-Analysis

    Summary: Women should be aware of their true risk of developing breast cancer and the limitations of current evidence when considering risk-reducing mastectomy. (Cochrane Library)

    • Does oophorectomy reduce breast cancer mortality for BRCA mutation carriers after breast cancer?
    • Jacobson M, Narod SA.
    • Expert Rev Anticancer Ther. 2018 Apr;18(4):305-306. doi: 10.1080/14737140.2018.1438891. Epub 2018 Feb 16.
    • Commercially Available Lifestyle Modification Program Decreases Inflammatory Biomarkers in BRCA1/2+ Breast Cancer Survivors.
    • Sturgeon KM, Foo W, Schmitz KH/
    • Cancer Epidemiol Biomarkers Prev. 2018 Mar;27(3):357-357. doi: 10.1158/1055-9965.EPI-18-0063.
    • Conference abstract
    • Breast tissue density change after oophorectomy in BRCA mutation carrier patients using visual & volumetric analysis.
    • Lecler A, Dunant A, Delaloge S, Wehrer D, Moussa T, Caron O, Balleyguier C.
    • Br J Radiol. 2018 Feb;91(1083):20170163. doi: 10.1259/bjr.20170163. Epub 2018 Jan 5.
    • Influence of Risk Category and Screening Round on the Performance of an MR Imaging and Mammography Screening Program in Carriers of the BRCA Mutation and Other Women at Increased Risk.
    • Vreemann S, Gubern-Mérida A, Schlooz-Vries MS, Bult P, van Gils CH, Hoogerbrugge N, Karssemeijer N, Mann RM.
    • Radiology. 2018 Feb;286(2):443-451. doi: 10.1148/radiol.2017170458. Epub 2017 Oct 16.
    • The Use of Sentinel Lymph Node Biopsy in BRCA1/2 Mutation Carriers Undergoing Prophylactic Mastectomy: A Retrospective Consecutive Case-Series Study.
    • Câmara S, Pereira D, André S, Mira B, Vaz F, Oom R, Marques JC, Leal de Faria J, Rodrigues Dos Santos C.
    • Int J Breast Cancer. 2018 Jan 1;2018:1426369. doi: 10.1155/2018/1426369. eCollection 2018.
    • Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
    • Soenderstrup IMH, Laenkholm AV, Jensen MB, Eriksen JO, Gerdes AM, Hansen TVO, Kruse TA, Larsen MJ, Pedersen IS, Rossing M, Thomassen M, Ejlertsen B.
    • Acta Oncol. 2018 Jan;57(1):95-101. doi: 10.1080/0284186X.2017.1398415. Epub 2017 Nov 22.
    • The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy.
    • Giannakeas V, Narod SA.
    • Breast Cancer Res Treat. 2018 Jan;167(1):263-267. doi: 10.1007/s10549-017-4476-1. Epub 2017 Sep 15.
    • Multi-institutional Evaluation of Women at High Risk of Developing Breast Cancer.
    • Hermel DJ, Wood ME, Chun J, Rounds T, Sands M, Schwartz S, Schnabel FR.
    • Clin Breast Cancer. 2017 Oct;17(6):427-432. doi: 10.1016/j.clbc.2017.04.005. Epub 2017 Apr 14.
    • Risk-reducing Salpingo-Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series.
    • Ricciardi E, Tomao F, Aletti G, Bazzurini L, Bocciolone L, Boveri S, Landoni F, Lapresa MT, Maruccio M, Parma G, Peccatori F, Petrella MC, Zanagnolo V, Colombo N, Maggioni A.
    • Anticancer Res. 2017 Sep;37(9):5241-5248.
    • Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers.
    • Havrilesky LJ, Moss HA, Chino J, Myers ER, Kauff ND.
    • Gynecol Oncol. 2017 Jun;145(3):549-554. doi: 10.1016/j.ygyno.2017.03.025. Epub 2017 Apr 6.
    • Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
    • McGee J, Giannakeas V, Karlan B, Lubinski J, Gronwald J, Rosen B, McLaughlin J, Risch H, Sun P, Foulkes WD, Neuhausen SL, Kotsopoulos J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.
    • Gynecol Oncol. 2017 May;145(2):346-351. doi: 10.1016/j.ygyno.2017.02.032. Epub 2017 Mar 14.
    • The effect of hormone therapy on quality of life and breast cancer risk after risk-reducing salpingo-oophorectomy: a systematic review.
    • Siyam T, Ross S, Campbell S, Eurich DT, Yuksel N.
    • BMC Womens Health. 2017 Mar 21;17(1):22. doi: 10.1186/s12905-017-0370-6.
    • STIC-ing with what we know.
    • Chen LM.
    • Gynecol Oncol. 2016 Nov;143(2):227-228. doi: 10.1016/j.ygyno.2016.10.007.
    • Editorial
    • Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers.
    • Zakhour M, Danovitch Y, Lester J, Rimel BJ, Walsh CS, Li AJ, Karlan BY, Cass I.
    • Gynecol Oncol. 2016 Nov;143(2):231-235. doi: 10.1016/j.ygyno.2016.08.336. Epub 2016 Sep 9.
    • Outcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033).
    • Davies KR, Brewster AM, Bedrosian I, Parker PA, Crosby MA, Peterson SK, Shen Y, Volk RJ, Cantor SB.
    • Breast Cancer Res. 2016 Sep 20;18(1):93. doi: 10.1186/s13058-016-0752-y.
    • Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
    • Kotsopoulos J, Huzarski T, Gronwald J, Singer CF, Moller P, Lynch HT, Armel S, Karlan B, Foulkes WD, Neuhausen SL, Senter L, Tung N, Weitzel JN, Eisen A, Metcalfe K, Eng C, Pal T, Evans G, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.
    • J Natl Cancer Inst. 2016 Sep 6;109(1). pii: djw177. doi: 10.1093/jnci/djw177. Print 2017 Jan.
    • Occult Histopathology and Its Predictors in Contralateral and Bilateral Prophylactic Mastectomies.
    • Mattos D, Gfrerer L, Ling IT, Reish RG, Hughes KS, Halpern EF, Cetrulo C, Colwell AS, Winograd JM, Yaremchuk MJ, Austen WG Jr, Liao EC.
    • Ann Surg Oncol. 2016 Mar;23(3):767-75. doi: 10.1245/s10434-015-4896-2. Epub 2015 Nov 17.
    • Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study.
    • Podo F, Santoro F, Di Leo G, Manoukian S, de Giacomi C, Corcione S, Cortesi L, Carbonaro LA, Trimboli RM, Cilotti A, Preda L, Bonanni B, Pensabene M, Martincich L, Savarese A, Contegiacomo A, Sardanelli F.
    • Clin Cancer Res. 2016 Feb 15;22(4):895-904. doi: 10.1158/1078-0432.CCR-15-0459. Epub 2015 Oct 26.
    • Contralateral Prophylactic Mastectomy: Factors Predictive of Occult Malignancy or High-Risk Lesion and the Impact of MRI and Genetic Testing.
    • Erdahl LM, Boughey JC, Hoskin TL, Degnim AC, Hieken TJ.
    • Ann Surg Oncol. 2016 Jan;23(1):72-7. doi: 10.1245/s10434-015-4660-7. Epub 2015 Jun 12.
    • Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis.
    • Basu NN, Ingham S, Hodson J, Lalloo F, Bulman M, Howell A, Evans DG.
    • Fam Cancer. 2015 Dec;14(4):531-8. doi: 10.1007/s10689-015-9825-9.
    • Frequency of diagnosis of cancer or high-risk lesion at operation for pathologic nipple discharge.
    • Dupont SC, Boughey JC, Jimenez RE, Hoskin TL, Hieken TJ.
    • Surgery. 2015 Oct;158(4):988-95. doi: 10.1016/j.surg.2015.05.020. Epub 2015 Aug 1.
    • Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study.
    • Segev Y, Rosen B, Lubinski J, Gronwald J, Lynch HT, Moller P, Kim-Sing C, Ghadirian P, Karlan B, Eng C, Gilchrist D, Neuhausen SL, Eisen A, Friedman E, Euhus D, Ping S, Narod SA; Hereditary Breast Cancer Study Group.
    • Fam Cancer. 2015 Sep;14(3):383-91. doi: 10.1007/s10689-015-9798-8.
    • Breast cancer after prophylactic mastectomy (bilateral or contralateral prophylactic mastectomy), a clinical entity: presentation, management, and outcomes.
    • Mutter RW, Frost MH, Hoskin TL, Johnson JL, Hartmann LC, Boughey JC.
    • Breast Cancer Res Treat. 2015 Aug;153(1):183-90. doi: 10.1007/s10549-015-3515-z. Epub 2015 Jul 26.
    • Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers.
    • Wu S, Weinstein SP, DeLeo MJ 3rd, Conant EF, Chen J, Domchek SM, Kontos D.
    • Breast Cancer Res. 2015 May 19;17(1):67. doi: 10.1186/s13058-015-0577-0.
    • Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation.
    • Finch AP, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, Rosen B, Maehle L, Ghadirian P, Cybulski C, Huzarski T, Eisen A, Foulkes WD, Kim-Sing C, Ainsworth P, Tung N, Lynch HT, Neuhausen S, Metcalfe KA, Thompson I, Murphy J, Sun P, Narod SA.
    • J Clin Oncol. 2014 May 20;32(15):1547-53. doi: 10.1200/JCO.2013.53.2820. Epub 2014 Feb 24.

    Comment, Editorial:

    A major step forward for BRCA1/2-related cancer risk management.

    Research news: Oophorectomy in women with BRCA1 or BRCA2 mutations. (Lancet Oncology)

    Press: Early Surgery in BRCA1 Carriers Lowers Ovarian Cancer Risk. (Medscape)

    Press: Young women with BRCA1 mutation 'should remove ovaries earlier'. (Medical News Today)

    • Ki-67 and p53 expression of the fallopian tube mucosa in breast cancer patients with hereditary risk.
    • Anton A, Schott S, Kaip G, Rath M, Heil J, Aulmann S, Sinn HP.
    • Arch Gynecol Obstet. 2014 May;289(5):1079-85. doi: 10.1007/s00404-013-3062-y. Epub 2013 Nov 7.
    • Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral.
    • Ingham SL, Sperrin M, Baildam A, Ross GL, Clayton R, Lalloo F, Buchan I, Howell A, Evans DG.
    • Breast Cancer Res Treat. 2013 Dec;142(3):611-8. doi: 10.1007/s10549-013-2765-x. Epub 2013 Nov 20.
    • Increased Proliferative Background in Healthy Women with BRCA1/2 Haploinsufficiency Is Associated with High Risk for Breast Cancer.
    • Nisman B, Kadouri L, Allweis T, Maly B, Hamburger T, Gronowitz S, Peretz T.
    • Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2110-5. doi: 10.1158/1055-9965.EPI-13-0193. Epub 2013 Aug 21.
    • Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis.
    • Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A, Tilanus-Linthorst MM, Koppert LB, Obdeijn IM, van Deurzen CH, Collée JM, Seynaeve C, Hooning MJ.
    • Ann Oncol. 2013 Aug;24(8):2029-35. doi: 10.1093/annonc/mdt134. Epub 2013 Apr 10.
    • Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer.
    • Evans DG, Ingham SL, Baildam A, Ross GL, Lalloo F, Buchan I, Howell A.
    • Breast Cancer Res Treat. 2013 Jul;140(1):135-42. doi: 10.1007/s10549-013-2583-1. Epub 2013 Jun 20.
    • Pulmonary embolism after abdominal flap breast reconstruction: prediction and prevention.
    • Enajat M, Damen TH, Geenen A, Timman R, van der Hulst RR, Mureau MA.
    • Plast Reconstr Surg. 2013 Jun;131(6):1213-22. doi: 10.1097/PRS.0b013e31828bd35e.
    • Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program.
    • Møller P, Stormorken A, Jonsrud C, Holmen MM, Hagen AI, Clark N, Vabø A, Sun P, Narod SA, Mæhle L.
    • Breast Cancer Res Treat. 2013 May;139(1):155-61. doi: 10.1007/s10549-013-2540-z. Epub 2013 Apr 25.
    • High-Grade Serous Tumor Arising from Fallopian Tube in a BRCA Mutation Carrier after Prophylactic Oophorectomy.
    • Lorusso D, Di Rocco R, Mancini M, Raspagliesi F.
    • Case Rep Oncol. 2013 Jan;6(1):21-4. doi: 10.1159/000346339. Epub 2013 Jan 9.
    • Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers.
    • Fakkert IE, Mourits MJ, Jansen L, van der Kolk DM, Meijer K, Oosterwijk JC, van der Vegt B, Greuter MJ, de Bock GH.
    • Cancer Prev Res (Phila). 2012 Nov;5(11):1291-7. doi: 10.1158/1940-6207.CAPR-12-0190. Epub 2012 Sep 25.
    • Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations.
    • de Bruin MA, Kwong A, Goldstein BA, Lipson JA, Ikeda DM, McPherson L, Sharma B, Kardashian A, Schackmann E, Kingham KE, Mills MA, West DW, Ford JM, Kurian AW.
    • Fam Cancer. 2012 Sep;11(3):429-39. doi: 10.1007/s10689-012-9531-9.
    • [Surgical prevention of breast carcinoma in patients with hereditary risk].
    • Dražan L, Veselý J, Hýža P, Kubek T, Foretová L, Coufal O.
    • Klin Onkol. [2012 Aug;]25 Suppl:S78-83.
    • A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers.
    • Sigal BM, Munoz DF, Kurian AW, Plevritis SK.
    • Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1066-77. doi: 10.1158/1055-9965.EPI-12-0149. Epub 2012 May 3.
    • Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    • Kotsopoulos J, Lubinski J, Lynch HT, Kim-Sing C, Neuhausen S, Demsky R, Foulkes WD, Ghadirian P, Tung N, Ainsworth P, Senter L, Karlan B, Eisen A, Eng C, Weitzel J, Gilchrist DM, Blum JL, Zakalik D, Singer C, Fallen T, Ginsburg O, Huzarski T, Sun P, Narod SA.
    • Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1089-96. doi: 10.1158/1055-9965.EPI-12-0201. Epub 2012 May 7.

    Comment, Letter:

    Oophorectomy and breast cancer in BRCA mutation carriers--letter.

    • Postoophorectomy Estrogen Use and Breast Cancer Risk.
    • Nichols HB, Trentham-Dietz A, Newcomb PA, Titus LJ, Egan KM, Hampton JM, Visvanathan K.
    • Obstet Gynecol. 2012 Jul;120(1):27-36.

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: hormonal birth control with ATM mutations?

    Comment:

    Post-oophorectomy estrogen use and breast cancer risk.

    • Bilateral oophorectomy, body mass index, and mortality in U.S. women aged 40 years and older.
    • McCarthy AM, Menke A, Ouyang P, Visvanathan K.
    • Cancer Prev Res (Phila). 2012 Jun;5(6):847-54. doi: 10.1158/1940-6207.CAPR-11-0430. Epub 2012 May 3.
    • Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.
    • Finkelman BS, Rubinstein WS, Friedman S, Friebel TM, Dubitsky S, Schonberger NS, Shoretz R, Singer CF, Blum JL, Tung N, Olopade OI, Weitzel JN, Lynch HT, Snyder C, Garber JE, Schildkraut J, Daly MB, Isaacs C, Pichert G, Neuhausen SL, Couch FJ, van't Veer L, Eeles R, Bancroft E, Evans DG, Ganz PA, Tomlinson GE, Narod SA, Matloff E, Domchek S, Rebbeck TR.
    • J Clin Oncol. 2012 Apr 20;30(12):1321-8. doi: 10.1200/JCO.2011.37.8133. Epub 2012 Mar 19.
    • Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy.
    • Cohen JV, Chiel L, Boghossian L, Jones M, Stopfer JE, Powers J, Rebbeck TR, Nathanson KL, Domchek SM.
    • Fam Cancer. 2012 Mar;11(1):69-75. doi: 10.1007/s10689-011-9480-8.
    • Online tool to guide decisions for BRCA1/2 mutation carriers.
    • Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, Mills MA, Plevritis SK.
    • J Clin Oncol. 2012 Feb 10;30(5):497-506. doi: 10.1200/JCO.2011.38.6060. Epub 2012 Jan 9.

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: An Online BRCA Positive Decision Guidance Tool.

    Comment:

    Are we ready for online tools in decision making for BRCA1/2 mutation carriers?

    Press: Are We Ready for Online Tools in Decision Making for BRCA1/2 Mutation Carriers? (Journal of Clinical Oncology)

    Press: Online tool helps those with BRCA mutations understand options. (Medical Xpress)

    • Physician data query (PDQ®) update.
    • [No authors listed]
    • J Natl Cancer Inst. 2012 Feb 8;104(3):176. doi: 10.1093/jnci/djs025. Epub 2012 Jan 23.